Proliferation of Tau 304–380 Fragment Aggregates through Autocatalytic Secondary Nucleation

Diana C. Rodriguez Camargo, Eimantas Šileikis, Sean Chia, Emil Axell, Katja Bernfur, Rodrigo Cataldi, Samuel I. A. Cohen, Georg Meisl, Johnny Habchi, Tuomas P. J. Knowles, Michele Vendruscolo, Sara LinseACS 2021 · DOI

TL;DR

This study elucidates the molecular mechanism behind the aggregation of a key tau protein fragment (residues 304-380) implicated in Alzheimer's disease. By employing a rigorous in vitro approach, the researchers demonstrate that tau aggregation is primarily driven by "secondary nucleation" on existing fibril surfaces, a process that amplifies aggregate formation autocatalytically. This finding offers a crucial framework for understanding tauopathies and developing targeted therapeutic interventions.

What Problem Does This Paper Address?

Alzheimer's disease (AD) and other tauopathies are characterized by the pathological self-assembly of the tau protein into neurofibrillary tangles within brain cells. Despite this being a hallmark of these devastating neurodegenerative diseases, the precise molecular mechanisms governing tau aggregation remain largely elusive. Previous research has often relied on additives or harsh conditions to induce aggregation, making it difficult to study the intrinsic process. This paper aims to address this knowledge gap by establishing a reproducible in vitro system to study the spontaneous aggregation of a specific, aggregation-prone tau fragment under quiescent, physiological conditions, thereby uncovering the fundamental steps involved.

Methods

The researchers developed a multi-step purification protocol to obtain an ultrapure, monomeric form of the tau 304-380 fragment, with a specific cysteine residue (Cys322) mutated to serine to prevent unwanted dimerization. This purified fragment was then subjected to spontaneous aggregation assays under quiescent conditions.

Key techniques employed include:

  • Fluorescence Spectroscopy: Using the amyloid-specific dye X34, the kinetics of fibril formation were monitored in real-time. X34 binds to the β-sheet structure of amyloid fibrils, leading to a measurable increase in fluorescence.
  • Mass Spectrometry (MS): Specifically, Liquid Chromatography-Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (LC-MALDI-TOF) MS was used. This technique, combined with the use of isotopically labeled monomers (¹⁴N and ¹⁵N), was crucial for tracing the origin of intermediate oligomeric species.
  • Cryo-Electron Microscopy (Cryo-EM): This technique was used to visualize the morphology of the formed tau aggregates, confirming the presence of amyloid fibrils.
  • Global Kinetics Analysis: This computational approach was used to fit the experimental aggregation data to various mechanistic models, allowing the researchers to identify the most likely sequence of molecular events.

Datasets

Not discussed in the paper. The study relies on in vitro experimental data generated by the researchers.

Key Insights and Ideas

  • Dominance of Secondary Processes: The study definitively shows that once initial tau aggregates (fibrils) are formed, the subsequent proliferation of these aggregates is not driven by primary nucleation (slow, de novo formation) or fragmentation, but rather by "secondary nucleation" – the formation of new aggregates on the surface of existing fibrils.
  • Autocatalytic Amplification: Secondary nucleation is an autocatalytic process, meaning the presence of existing aggregates accelerates the formation of new ones. This creates a powerful feedback loop that can lead to rapid aggregate proliferation, a key feature of tauopathy progression.
  • Monomers as the Source of New Oligomers: Through sophisticated isotopic labeling and mass spectrometry, the researchers proved that the intermediate oligomeric species observed during aggregation are predominantly formed from free tau monomers, not from the fragmentation of existing fibrils.
  • Slow Primary Nucleation: In contrast to secondary processes, the initial formation of tau fibrils (primary nucleation) is found to be a slow step, contributing to the observed lag phase in aggregation kinetics.
  • Mechanistic Parallels with Aβ: The findings highlight a striking similarity in the aggregation mechanisms of tau and amyloid-beta (Aβ), another protein implicated in AD. Both proteins appear to aggregate via secondary nucleation, suggesting that therapeutic strategies targeting this mechanism might be effective for both proteinopathies.

Key Results

  • Reproducible Kinetics: The developed protocol allowed for reproducible aggregation kinetics of the tau 304-380 fragment over a wide range of concentrations (1-200 µM) under quiescent conditions.
  • Model Fit: A kinetic model incorporating primary nucleation, elongation, and multistep secondary nucleation of monomers on fibril surfaces provided a significantly better fit to the experimental data than models lacking secondary processes.
  • Isotopic Evidence: Mass spectrometry experiments using ¹⁴N monomers and ¹⁵N seeds showed that oligomers were composed almost entirely of ¹⁴N, strongly indicating that monomers are the source of new aggregate formation, ruling out fragmentation as a major pathway.
  • Comparison to Aβ42: The estimated rate constant products for tau aggregation suggest that primary nucleation is significantly slower for the tau fragment compared to Aβ42, while secondary processes are more comparable.

Limitations and Future Work

  • Fragment vs. Full-Length Tau: The study focuses on a specific fragment (304-380) of tau. While this fragment represents a key aggregation-prone region, the aggregation behavior of full-length tau isoforms, especially those with post-translational modifications, may differ. The authors suggest that similar seeded aggregation kinetics approaches could be applied to full-length tau, though longer experimental time scales might be required due to potentially higher solubility and longer lag times.
  • Discrimination Between Secondary Processes: While the data strongly favor secondary nucleation over fragmentation, the authors acknowledge that the kinetic models for these two processes provided only a slightly better fit for secondary nucleation. The isotopic labeling experiments were crucial for definitively distinguishing between these two pathways.
  • In Vivo Relevance: While the in vitro findings provide a mechanistic framework, further studies are needed to fully understand how these processes translate to the complex cellular environment and in vivo progression of tauopathies.

The authors suggest that their findings provide a framework for understanding tau aggregation in disease and for selecting tau forms as therapeutic targets. The similarity to Aβ aggregation mechanisms also opens avenues for repurposing or adapting existing therapeutic strategies.

Summary updated

Abstract

The self-assembly of the protein tau into neurofibrillary tangles is one of the hallmarks of Alzheimer's disease and related tauopathies. Still, the molecular mechanism of tau aggregation is largely unknown. This problem may be addressed by systematically obtaining reproducible in vitro kinetics measurements under quiescent conditions in the absence of triggering substances. Here, we implement this strategy by developing protocols for obtaining an ultrapure tau fragment (residues 304-380 of tau441) and for performing spontaneous aggregation assays with reproducible kinetics under quiescent conditions. We are thus able to identify the mechanism of fibril formation of the tau 304-380 fragment at physiological pH using fluorescence spectroscopy and mass spectrometry. We find that primary nucleation is slow, and that secondary processes dominate the aggregation process once the initial aggregates are formed. Moreover, our results further show that secondary nucleation of monomers on fibril surfaces dominates over fragmentation of fibrils. Using separate isotopes in monomers and fibrils, through mass spectroscopy measurements, we verify the isotope composition of the intermediate oligomeric species, which reveals that these small aggregates are generated from monomer through secondary nucleation. Our results provide a framework for understanding the processes leading to tau aggregation in disease and for selecting possible tau forms as targets in the development of therapeutic interventions in Alzheimer's disease.
BibTeX
@inproceedings{camargo2021proliferation,
  author = {Diana C. Rodriguez Camargo and Eimantas Šileikis and Sean Chia and Emil Axell and Katja Bernfur and Rodrigo Cataldi and Samuel I. A. Cohen and Georg Meisl and Johnny Habchi and Tuomas P. J. Knowles and Michele Vendruscolo and Sara Linse},
  title = {{Proliferation of Tau 304–380 Fragment Aggregates through Autocatalytic Secondary Nucleation}},
  booktitle = {ACS},
  year = {2021},
  doi = {10.1021/acschemneuro.1c00454},
}
Figure